Poxel to Present Promising Rare Disease Treatment at International Meeting on AMPK

Poxel SA, a clinical stage biopharmaceutical company, is set to participate in the 12th International Meeting on AMPK, where it will showcase its innovative treatment for rare metabolic diseases. Sophie Bozec, Executive Vice President of R&D Pharmacology and Scientific Communication at Poxel, will deliver a virtual presentation titled “Direct AMPK Activation: From Preclinical to Clinical. Perspectives in Rare Metabolic Diseases.”

During the presentation, Bozec will provide an overview of Poxel’s molecule PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. Poxel’s focus is on developing treatments for rare diseases such as adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD).

Poxel has already achieved significant milestones in its quest to address chronic serious diseases with metabolic pathophysiology. In the treatment of non-alcoholic steatohepatitis (NASH), PXL065 (deuterium-stabilized R-pioglitazone) successfully met its primary endpoint in the streamlined Phase 2 trial, DESTINY-1. Additionally, Poxel’s TWYMEEG® (Imeglimin), a first-in-class product targeting mitochondrial dysfunction, is currently marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma.

With headquarters in Lyon, France, Poxel has established strategic partnerships with Sumitomo Pharma for Imeglimin in Japan, China, and eleven other Asian countries. The company also has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information about Poxel and its innovative treatments, please visit www.poxelpharma.com.